2,000 Shares in Cabot Co. (NYSE:CBT) Acquired by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC bought a new stake in shares of Cabot Co. (NYSE:CBT) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,000 shares of the specialty chemicals company’s stock, valued at approximately $224,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Copeland Capital Management LLC increased its holdings in shares of Cabot by 30.4% during the third quarter. Copeland Capital Management LLC now owns 626,253 shares of the specialty chemicals company’s stock valued at $69,996,000 after purchasing an additional 146,179 shares during the period. Assenagon Asset Management S.A. grew its position in Cabot by 571.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 127,116 shares of the specialty chemicals company’s stock valued at $11,681,000 after buying an additional 108,197 shares in the last quarter. Capital Research Global Investors increased its stake in Cabot by 22.9% during the 1st quarter. Capital Research Global Investors now owns 521,486 shares of the specialty chemicals company’s stock valued at $48,081,000 after buying an additional 97,101 shares during the period. Earnest Partners LLC raised its position in shares of Cabot by 2.4% during the 2nd quarter. Earnest Partners LLC now owns 3,363,398 shares of the specialty chemicals company’s stock worth $309,063,000 after buying an additional 80,096 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Cabot by 7.3% in the 2nd quarter. American Century Companies Inc. now owns 976,709 shares of the specialty chemicals company’s stock worth $89,750,000 after acquiring an additional 66,171 shares during the period. Institutional investors own 93.18% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Sean D. Keohane sold 25,617 shares of Cabot stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $101.55, for a total value of $2,601,406.35. Following the transaction, the chief executive officer now directly owns 331,174 shares of the company’s stock, valued at $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Sean D. Keohane sold 25,617 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the completion of the sale, the chief executive officer now owns 331,174 shares of the company’s stock, valued at $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Erica Mclaughlin sold 23,274 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $99.79, for a total value of $2,322,512.46. Following the transaction, the chief financial officer now directly owns 59,814 shares in the company, valued at $5,968,839.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,939 shares of company stock worth $7,308,812. Company insiders own 3.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CBT shares. UBS Group dropped their target price on Cabot from $103.00 to $98.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th. JPMorgan Chase & Co. boosted their price objective on Cabot from $95.00 to $105.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $101.75.

Cabot Trading Down 1.0 %

Shares of NYSE:CBT opened at $109.26 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.45 and a current ratio of 2.22. The stock has a market capitalization of $6.04 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 0.93 and a beta of 1.19. Cabot Co. has a 1-year low of $65.10 and a 1-year high of $117.14. The company has a 50 day moving average price of $107.40 and a 200 day moving average price of $100.28.

Cabot (NYSE:CBT) last issued its earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the firm posted $1.42 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, research analysts anticipate that Cabot Co. will post 7.07 EPS for the current fiscal year.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.